SPECC1P2

Across TCGA pan-cancer cohorts, SPECC1P2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SPECC1P2 data layer compared with 12 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SPECC1P2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPECC1P2 expression acts as an unfavorable survival marker.

LUAD and LIHC are the cancer types where SPECC1P2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.258	0.812	.004	12	view →
LIHC	DFS	Median	All	0.080	0.553	.004	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SPECC1P2–LUAD (OS)

Open the LUAD breakdown →